- Home
- OCUL
as 11-15-2024 4:00pm EST
Ocular Therapeutix Inc is a biotechnology company that specializes in therapies for diseases and conditions of the eye. The company uses its proprietary hydrogel platform technology to deliver therapeutic agents to the eye. Its pipeline consists of eye medication that aims to overcome the limitations of current eye-drop-based therapies for ophthalmic diseases and conditions. Its pipeline product includes Dextenza, OTX-TIC, OTX-TKI, and OTX-IVT.
| Founded: | 2006 | Country: | United States |
| Employees: | N/A | City: | BEDFORD |
| Market Cap: | 1.4B | IPO Year: | 2014 |
| Target Price: | $16.50 | AVG Volume (30 days): | 889.3K |
| Analyst Decision: | Strong Buy | Number of Analysts: | 8 |
| Dividend Yield: | N/A | Dividend Payout Frequency: | N/A |
| EPS: | -1.27 | EPS Growth: | N/A |
| 52 Week Low/High: | $2.05 - $11.78 | Next Earning Date: | 11-14-2024 |
| Revenue: | $61,442,000 | Revenue Growth: | 6.45% |
| Revenue Growth (this year): | 15.49% | Revenue Growth (next year): | 13.31% |
Stock Insider Trading Activity of Ocular Therapeutix Inc. (OCUL)
| Name | Ticker | Relationship | Date | Transaction | AVG Cost Per Share | Shares | Total Value | Securities Owned After Transaction(s) | SEC Form 4 |
|---|---|---|---|---|---|---|---|---|---|
| Nayak Sanjay | OCUL | Chief Strategy Officer | Aug 23 '24 | Sell | $9.02 | 1,832 | $16,524.64 | 176,194 | |
| Dugel Pravin | OCUL | See Remarks | Aug 23 '24 | Sell | $9.02 | 20,880 | $188,337.60 | 812,473 |
Latest Ocular Therapeutix Inc. News
OCUL Breaking Stock News: Dive into OCUL Ticker-Specific Updates for Smart Investing
GuruFocus.com
2 days ago
Ocular Therapeutix Inc (OCUL) Q3 2024 Earnings Call Highlights: Strong Financial Position and ...
Zacks
3 days ago
Ocular Therapeutix (OCUL) Reports Q3 Loss, Lags Revenue Estimates
Associated Press Finance
3 days ago
Ocular Therapeutix: Q3 Earnings Snapshot
MT Newswires
3 days ago
Ocular Therapeutix Q3 Net Loss Narrows as Revenue Increases
GlobeNewswire
3 days ago
Ocular Therapeutix™ Reports Third Quarter 2024 Results and Business Highlights
Zacks
4 days ago
Harrow (HROW) Reports Q3 Loss, Lags Revenue Estimates
GlobeNewswire
4 days ago
Ocular Therapeutix™ to Present at the Jefferies London Healthcare Conference and Ophthalmology Innovation Summit XIV
GuruFocus.com
4 days ago
What To Expect From Ocular Therapeutix Inc (OCUL) Q3 2024 Earnings
Compare OCUL vs Leading Stocks
Share on Social Networks:
Disclaimer
The information presented on this page, "OCUL Ocular Therapeutix Inc. - Stocks Price | History | Analysis", including historical data, forecasts, news, insider information, and predictions, is provided for educational purposes only. It should not be considered as financial advice or a recommendation to buy or sell any securities. Decisions regarding investments should be made only after careful consideration and consultation with a qualified financial advisor. We do not endorse or guarantee the accuracy or reliability of the information provided, and we disclaim any liability for financial losses incurred as a result of decisions made based on the information presented.